{"doc_id": "32423584", "type of study": "Therapy", "title": "", "abstract": "Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial.\nNo specific antiviral drug has been proven effective for treatment of patients with severe coronavirus disease 2019 (COVID-19).\nRemdesivir (GS-5734), a nucleoside analogue prodrug, has inhibitory effects on pathogenic animal and human coronaviruses, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in vitro, and inhibits Middle East respiratory syndrome coronavirus, SARS-CoV-1, and SARS-CoV-2 replication in animal models.\nWe did a randomised, double-blind, placebo-controlled, multicentre trial at ten hospitals in Hubei, China.\nEligible patients were adults (aged \u226518 years) admitted to hospital with laboratory-confirmed SARS-CoV-2 infection, with an interval from symptom onset to enrolment of 12 days or less, oxygen saturation of 94% or less on room air or a ratio of arterial oxygen partial pressure to fractional inspired oxygen of 300 mm Hg or less, and radiologically confirmed pneumonia.\nPatients were randomly assigned in a 2:1 ratio to intravenous remdesivir (200 mg on day 1 followed by 100 mg on days 2-10 in single daily infusions) or the same volume of placebo infusions for 10 days.\nPatients were permitted concomitant use of lopinavir-ritonavir, interferons, and corticosteroids.\nThe primary endpoint was time to clinical improvement up to day 28, defined as the time (in days) from randomisation to the point of a decline of two levels on a six-point ordinal scale of clinical status (from 1=discharged to 6=death) or discharged alive from hospital, whichever came first.\nPrimary analysis was done in the intention-to-treat (ITT) population and safety analysis was done in all patients who started their assigned treatment.\nThis trial is registered with ClinicalTrials.gov, NCT04257656.\nBetween Feb 6, 2020, and March 12, 2020, 237 patients were enrolled and randomly assigned to a treatment group (158 to remdesivir and 79 to placebo); one patient in the placebo group who withdrew after randomisation was not included in the ITT population.\nRemdesivir use was not associated with a difference in time to clinical improvement (hazard ratio 1\u00b723 [95% CI 0\u00b787-1\u00b775]).\nAlthough not statistically significant, patients receiving remdesivir had a numerically faster time to clinical improvement than those receiving placebo among patients with symptom duration of 10 days or less (hazard ratio 1\u00b752 [0\u00b795-2\u00b743]).\nAdverse events were reported in 102 (66%) of 155 remdesivir recipients versus 50 (64%) of 78 placebo recipients.\nRemdesivir was stopped early because of adverse events in 18 (12%) patients versus four (5%) patients who stopped placebo early.\nIn this study of adult patients admitted to hospital for severe COVID-19, remdesivir was not associated with statistically significant clinical benefits.\nHowever, the numerical reduction in time to clinical improvement in those treated earlier requires confirmation in larger studies.\nChinese Academy of Medical Sciences Emergency Project of COVID-19, National Key Research and Development Program of China, the Beijing Science and Technology Project.\nCopyright \u00a9 2020 Elsevier Ltd. All rights reserved.\n", "Evidence Map": {"Enrollment": [{"term": "adults", "negation": "affirmed", "UMLS": {}, "start": 14, "end": 20}, {"term": "severe COVID-19", "negation": "affirmed", "UMLS": {}, "start": 26, "end": 41}, {"term": "adults", "negation": "affirmed", "UMLS": {}, "start": 23, "end": 29}, {"term": "admitted to hospital", "negation": "affirmed", "UMLS": {}, "start": 49, "end": 69}, {"term": "laboratory-confirmed SARS-CoV-2 infection", "negation": "affirmed", "UMLS": {}, "start": 75, "end": 116}, {"term": "interval from symptom onset to enrolment of 12 days or less", "negation": "affirmed", "UMLS": {}, "start": 127, "end": 186}, {"term": "oxygen saturation of 94 % or less on room air", "negation": "affirmed", "UMLS": {}, "start": 189, "end": 234}, {"term": "ratio of arterial oxygen partial pressure to fractional inspired oxygen of 300 mm Hg or", "negation": "affirmed", "UMLS": {}, "start": 240, "end": 327}, {"term": "symptom duration of 10 days or less", "negation": "negated", "UMLS": {}, "start": 174, "end": 209}, {"term": "adult", "negation": "affirmed", "UMLS": {}, "start": 17, "end": 22}, {"term": "admitted to hospital", "negation": "affirmed", "UMLS": {}, "start": 32, "end": 52}, {"term": "severe COVID-19", "negation": "affirmed", "UMLS": {}, "start": 57, "end": 72}], "Comparison Results": [], "Study Arm 1 Results": [], "Study Arm 2 Results": [], "Hypothesis": []}, "Sentence-level breakdown": [{"Section": "TITLE", "Text": "Remdesivir in adults with severe COVID-19 : a randomised , double-blind , placebo-controlled , multicentre trial .", "Evidence Elements": {"Participant": [{"term": "adults", "negation": "affirmed", "UMLS": {}, "start": 14, "end": 20}, {"term": "severe COVID-19", "negation": "affirmed", "UMLS": {}, "start": 26, "end": 41}], "Intervention": [{"term": "Remdesivir", "negation": "affirmed", "UMLS": {}, "start": 0, "end": 10}], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "BACKGROUND", "Text": "No specific antiviral drug has been proven effective for treatment of patients with severe coronavirus disease 2019 ( COVID-19 ) .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "BACKGROUND", "Text": "Remdesivir ( GS-5734 ) , a nucleoside analogue prodrug , has inhibitory effects on pathogenic animal and human coronaviruses , including severe acute respiratory syndrome coronavirus 2 ( SARS-CoV-2 ) in vitro , and inhibits Middle East respiratory syndrome coronavirus , SARS-CoV-1 , and SARS-CoV-2 replication in animal models .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "METHODS", "Text": "We did a randomised , double-blind , placebo-controlled , multicentre trial at ten hospitals in Hubei , China .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "METHODS", "Text": "Eligible patients were adults ( aged \u226518 years ) admitted to hospital with laboratory-confirmed SARS-CoV-2 infection , with an interval from symptom onset to enrolment of 12 days or less , oxygen saturation of 94 % or less on room air or a ratio of arterial oxygen partial pressure to fractional inspired oxygen of 300 mm Hg or less , and radiologically confirmed pneumonia .", "Evidence Elements": {"Participant": [{"term": "adults", "negation": "affirmed", "UMLS": {}, "start": 23, "end": 29}, {"term": "admitted to hospital", "negation": "affirmed", "UMLS": {}, "start": 49, "end": 69}, {"term": "laboratory-confirmed SARS-CoV-2 infection", "negation": "affirmed", "UMLS": {}, "start": 75, "end": 116}, {"term": "interval from symptom onset to enrolment of 12 days or less", "negation": "affirmed", "UMLS": {}, "start": 127, "end": 186}, {"term": "oxygen saturation of 94 % or less on room air", "negation": "affirmed", "UMLS": {}, "start": 189, "end": 234}, {"term": "ratio of arterial oxygen partial pressure to fractional inspired oxygen of 300 mm Hg or", "negation": "affirmed", "UMLS": {}, "start": 240, "end": 327}], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "METHODS", "Text": "Patients were randomly assigned in a 2:1 ratio to intravenous remdesivir ( 200 mg on day 1 followed by 100 mg on days 2-10 in single daily infusions ) or the same volume of placebo infusions for 10 days .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "remdesivir", "negation": "affirmed", "UMLS": {}, "start": 62, "end": 72}, {"term": "placebo", "negation": "affirmed", "UMLS": {}, "start": 173, "end": 180}], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "METHODS", "Text": "Patients were permitted concomitant use of lopinavir-ritonavir , interferons , and corticosteroids .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "METHODS", "Text": "The primary endpoint was time to clinical improvement up to day 28 , defined as the time ( in days ) from randomisation to the point of a decline of two levels on a six-point ordinal scale of clinical status ( from 1=discharged to 6=death ) or discharged alive from hospital , whichever came first .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [{"term": "time to clinical improvement", "negation": "affirmed", "UMLS": {}, "start": 25, "end": 53}, {"term": "decline of two levels", "negation": "affirmed", "UMLS": {}, "start": 138, "end": 159}, {"term": "discharged alive", "negation": "affirmed", "UMLS": {}, "start": 244, "end": 260}], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "METHODS", "Text": "Primary analysis was done in the intention-to-treat ( ITT ) population and safety analysis was done in all patients who started their assigned treatment .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "METHODS", "Text": "This trial is registered with ClinicalTrials.gov , NCT04257656 .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "FINDINGS", "Text": "Between Feb 6 , 2020 , and March 12 , 2020 , 237 patients were enrolled and randomly assigned to a treatment group ( 158 to remdesivir and 79 to placebo ) ; one patient in the placebo group who withdrew after randomisation was not included in the ITT population .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "remdesivir", "negation": "affirmed", "UMLS": {}, "start": 124, "end": 134}, {"term": "placebo", "negation": "affirmed", "UMLS": {}, "start": 145, "end": 152}, {"term": "placebo", "negation": "affirmed", "UMLS": {}, "start": 145, "end": 152}], "Outcome": [{"term": "withdrew", "negation": "affirmed", "UMLS": {}, "start": 194, "end": 202}], "Observation": [], "Count": [{"term": "one patient", "negation": "affirmed", "UMLS": {}, "start": 157, "end": 168}]}, "Evidence Propositions": [{"Intervention": "placebo", "Observation": "", "Count": "one patient", "Outcome": "withdrew"}]}, {"Section": "FINDINGS", "Text": "Remdesivir use was not associated with a difference in time to clinical improvement ( hazard ratio 1\u00b723 [ 95 % CI 0\u00b787-1\u00b775 ] ) .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "Remdesivir", "negation": "affirmed", "UMLS": {}, "start": 0, "end": 10}], "Outcome": [{"term": "time to clinical improvement", "negation": "negated", "UMLS": {}, "start": 55, "end": 83}], "Observation": [{"term": "difference", "negation": "negated", "UMLS": {}, "start": 41, "end": 51}], "Count": []}, "Evidence Propositions": [{"Intervention": ["Remdesivir"], "Observation": "difference", "Outcome": "time to clinical improvement", "Count": ""}]}, {"Section": "FINDINGS", "Text": "Although not statistically significant , patients receiving remdesivir had a numerically faster time to clinical improvement than those receiving placebo among patients with symptom duration of 10 days or less ( hazard ratio 1\u00b752 [ 0\u00b795-2\u00b743 ] ) .", "Evidence Elements": {"Participant": [{"term": "symptom duration of 10 days or less", "negation": "negated", "UMLS": {}, "start": 174, "end": 209}], "Intervention": [{"term": "remdesivir", "negation": "negated", "UMLS": {}, "start": 60, "end": 70}, {"term": "placebo", "negation": "negated", "UMLS": {}, "start": 146, "end": 153}], "Outcome": [{"term": "time to clinical improvement", "negation": "negated", "UMLS": {}, "start": 96, "end": 124}], "Observation": [{"term": "numerically faster", "negation": "negated", "UMLS": {}, "start": 77, "end": 95}], "Count": []}, "Evidence Propositions": []}, {"Section": "FINDINGS", "Text": "Adverse events were reported in 102 ( 66 % ) of 155 remdesivir recipients versus 50 ( 64 % ) of 78 placebo recipients .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "remdesivir recipients", "negation": "affirmed", "UMLS": {}, "start": 52, "end": 73}], "Outcome": [{"term": "Adverse events", "negation": "affirmed", "UMLS": {}, "start": 0, "end": 14}], "Observation": [], "Count": [{"term": "102 ( 66 % ) of 155", "negation": "affirmed", "UMLS": {}, "start": 32, "end": 51}, {"term": "50 ( 64", "negation": "affirmed", "UMLS": {}, "start": 81, "end": 88}]}, "Evidence Propositions": []}, {"Section": "FINDINGS", "Text": "Remdesivir was stopped early because of adverse events in 18 ( 12 % ) patients versus four ( 5 % ) patients who stopped placebo early .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "Remdesivir", "negation": "affirmed", "UMLS": {}, "start": 0, "end": 10}], "Outcome": [{"term": "adverse events", "negation": "affirmed", "UMLS": {}, "start": 40, "end": 54}], "Observation": [], "Count": [{"term": "18 ( 12 % ) patients", "negation": "affirmed", "UMLS": {}, "start": 58, "end": 78}, {"term": "four ( 5 %", "negation": "affirmed", "UMLS": {}, "start": 86, "end": 96}]}, "Evidence Propositions": [{"Intervention": "Remdesivir", "Observation": "", "Count": "18 ( 12 % ) patients", "Outcome": "adverse events"}]}, {"Section": "INTERPRETATION", "Text": "In this study of adult patients admitted to hospital for severe COVID-19 , remdesivir was not associated with statistically significant clinical benefits .", "Evidence Elements": {"Participant": [{"term": "adult", "negation": "affirmed", "UMLS": {}, "start": 17, "end": 22}, {"term": "admitted to hospital", "negation": "affirmed", "UMLS": {}, "start": 32, "end": 52}, {"term": "severe COVID-19", "negation": "affirmed", "UMLS": {}, "start": 57, "end": 72}], "Intervention": [{"term": "remdesivir", "negation": "affirmed", "UMLS": {}, "start": 75, "end": 85}], "Outcome": [{"term": "clinical", "negation": "negated", "UMLS": {}, "start": 136, "end": 144}], "Observation": [{"term": "statistically significant", "negation": "negated", "UMLS": {}, "start": 110, "end": 135}], "Count": []}, "Evidence Propositions": []}, {"Section": "INTERPRETATION", "Text": "However , the numerical reduction in time to clinical improvement in those treated earlier requires confirmation in larger studies .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [{"term": "time to clinical improvement", "negation": "affirmed", "UMLS": {}, "start": 37, "end": 65}], "Observation": [{"term": "numerical reduction", "negation": "affirmed", "UMLS": {}, "start": 14, "end": 33}], "Count": []}, "Evidence Propositions": []}, {"Section": "FUNDING", "Text": "Chinese Academy of Medical Sciences Emergency Project of COVID-19 , National Key Research and Development Program of China , the Beijing Science and Technology Project .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "Copyright \u00a9 2020 Elsevier Ltd . All rights reserved .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}]}